Quality

X Financial Reports Second Quarter 2022 Unaudited Financial Results

Retrieved on: 
Monday, August 8, 2022 - 10:00pm

SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- X Financial (NYSE: XYF) (the "Company" or "we"), a leading online personal finance company in China, today announced its unaudited financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- X Financial (NYSE: XYF) (the "Company" or "we"), a leading online personal finance company in China, today announced its unaudited financial results for the second quarter ended June 30, 2022.
  • Income from operations in the second quarter of 2022 was RMB193.8 million (US$28.9 million), compared with RMB337.7 million in the same period of 2021.
  • Net income in the second quarter of 2022 was RMB185.7 million (US$27.7 million), compared with RMB223.4 million in the same period of 2021.
  • Net income for the second quarter of 2022 improved to RMB185.7 million from RMB139.9 million in the previous quarter, and Non-GAAP adjusted net income for the second quarter of 2022 was RMB210.7 million, representing an increase of 36.9% quarter-over-quarter.

Comtech Awarded Strategic Order of Next Generation ELEVATE™ VSAT Platform to Provide Premium Cellular Backhaul Connectivity in Latin America

Retrieved on: 
Monday, August 8, 2022 - 6:15pm

August 8, 2022-- Comtech Telecommunications Corp. (NASDAQ: CMTL) a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today that during its fourth quarter of fiscal 2022, it was awarded a strategic order for its Comtech ELEVATE VSAT platform from a Tier One global service operator to provide 4G/LTE cellular backhaul connectivity in Latin America.

Key Points: 
  • August 8, 2022-- Comtech Telecommunications Corp. (NASDAQ: CMTL) a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today that during its fourth quarter of fiscal 2022, it was awarded a strategic order for its Comtech ELEVATE VSAT platform from a Tier One global service operator to provide 4G/LTE cellular backhaul connectivity in Latin America.
  • The Comtech ELEVATE solution will enable this Tier One operator to expand its coverage across the region and improve Quality of Service and Quality of Experience for the users of cellular services.
  • We are proud to be part of this large project which will deliver mobile cellular connectivity to one of the worlds most populous regions.
  • Comtech has always been at the forefront of satellite backhaul technologies.

Woodstock Sterile Solutions Fills Two Leadership Roles

Retrieved on: 
Monday, August 8, 2022 - 2:00pm

WOODSTOCK, Ill., Aug. 8, 2022 /PRNewswire/ -- Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), announced today that it has named Dr. Kuljit Bhatia as the company's first Chief Scientific Officer and Sheila Moran as its Senior Vice President of Quality. Bhatia will lead the company's New Product Development department and is part of the organization's senior staff. Moran is responsible for the strategy, direction, and execution of all aspects of the company's quality initiatives, quality control and training programs.

Key Points: 
  • I am confident that he will be a success in this new role," says Paul Josephs, Chief Executive Officer at Woodstock Sterile Solutions.
  • He has more than 25 years of experience in drug product development, having also held leadership roles at Mylan, DPT Laboratories, Nycomed/Fougera Pharmaceuticals and Medicis.
  • Prior to joining Woodstock Sterile Solutions, she served as the Vice President of Quality for Xeris Pharmaceuticals,
    For more information on Woodstock Sterile Solutions, visit https://woodstocksterilesolutions.com .
  • For 50 years, Woodstock Sterile Solutions has been recognized as a leading Blow-Fill-Seal (BFS) Contract Development and Manufacturing Organization (CDMO).

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

Retrieved on: 
Monday, August 8, 2022 - 1:00pm

They are an ideal partner for us as we develop our FDA strategy in the United States.

Key Points: 
  • They are an ideal partner for us as we develop our FDA strategy in the United States.
  • "DXOCRO will spearhead both our clinical product development and our regulatory program in the United States, and seek to establish clinical utility for our Nu.Q products.
  • Through the conduct of Volition's clinical validation studies, we hope to validate a broad range of potential Nu.Q products and support Volition's U.S. commercialization strategy."
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, August 8, 2022 - 12:05pm

LEXINGTON, Mass. and AMSTERDAM, Aug. 08, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2022 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, Aug. 08, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2022 and highlighted recent progress across its business.
  • This follows the MAA submission by CSL Behring which was validated by the EMA in March 2022.
  • In June 2022, initial 12-month observations were announced on the lower-dose cohort of the double-blinded and randomized U.S.
  • uniQure management will host an investor conference call and webcast today, Monday, August 8, 2022, at 8:30 a.m.

Go-Live Faster Taps Proven Global Executives to Join Leadership Team

Retrieved on: 
Thursday, August 4, 2022 - 1:35pm

WILMINGTON, Del., Aug. 4, 2022 /PRNewswire-PRWeb/ -- Go-Live Faster, the Commercial Banking focused technology consulting firm whose productized solutions are fast-tracking the digital transformation of banks, announced the addition of two executives to its senior leadership team, significantly expanding its executive ranks and signaling a laser focus on strategy-driven market penetration. Global change agent Roy Stansbury and IT solutions delivery expert Krithika Kumar have joined Go-Live Faster as Executive Vice President, Strategic Initiatives, and Executive Vice President, Client Solutions and Delivery, respectively.

Key Points: 
  • Global change agent Roy Stansbury and IT solutions delivery expert Krithika Kumar have joined Go-Live Faster as Executive Vice President, Strategic Initiatives, and Executive Vice President, Client Solutions and Delivery, respectively.
  • "Roy's ability to build and scale cross-cultural teams is legendary," said Mukesh Mulchandani, CEO and Co-founder, Go-Live Faster.
  • Industry veteran Roy Stansbury brings a proven track record of transformative organizational success to his newly created position.
  • Founded in 2006, Go-Live Faster counts among its long-standing customer relationships, several mid-market and top 10 banks, each of whom have reaped the rewards of faster time to market.

Endologix Receives CE Mark Certification under EU-MDR for AFX®2 Endovascular AAA System

Retrieved on: 
Thursday, August 4, 2022 - 1:00pm

Endologix LLC , a privately held global medical device company dedicated to improving patients lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.

Key Points: 
  • Endologix LLC , a privately held global medical device company dedicated to improving patients lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.
  • CE Mark certification under the new requirements is a high-bar and we are proud of this significant company achievement.
  • Meeting the rigor of the new framework is an important milestone for our AFX2 System, said Elisa Hebb, Endologixs EVP of Medical, Clinical, Regulatory Affairs and Quality.
  • Endologixs current commercial EVAR products include the AFX2 Endovascular AAA System and the ALTO Abdominal Stent Graft System.

The IBSA Class40 – the Craft That Will Take Alberto Bona to the Route Du Rhum – Was Launched in Trinité-Sur-Mer

Retrieved on: 
Thursday, August 4, 2022 - 12:00pm

Latest-generation Class40, scow bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinit-Sur-Mer (Brittany, France).

Key Points: 
  • Latest-generation Class40, scow bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinit-Sur-Mer (Brittany, France).
  • Its a Mach 5 model, the latest evolution of Manuards Class40, and will be present at the start of the Route du Rhum as one of the most innovative and modern boats.
  • This boat perfectly reflects our approach to the program, summarised Alberto Bona.
  • It was a huge team effort, between us and IBSA, that led us to yesterdays technical launch, said Bona.

SIDM and Leapfrog Team Up Against the Growing Threat to Patient Survival Rates Posed by Diagnostic Errors in U.S. Hospitals

Retrieved on: 
Thursday, August 4, 2022 - 12:47pm

Of these, more than half a million diagnostic errors occur in U.S. hospitals and account for 40,000-80,000 inpatient deaths annually.

Key Points: 
  • Of these, more than half a million diagnostic errors occur in U.S. hospitals and account for 40,000-80,000 inpatient deaths annually.
  • The Society to Improve Diagnosis in Medicine (SIDM), in partnership with The Leapfrog Group, is working to reverse this unfortunate trend through the release of Recognizing Excellence in Diagnosis: Recommended Practices for Hospitals .
  • "The report recommends concrete, evidence-based practices that hospitals and systems of care can implement NOW, that will have an impact in reducing patient harm."
  • The Society to Improve Diagnosis in Medicine (SIDM) catalyzes and leads change to improve diagnosis and eliminate harm from diagnostic error.

Asia Pacific Healthcare Technology Management Market Report 2022-2028: Featuring Key Players General Electric, Siemens Healthineers, Koninklijke Philips & Others

Retrieved on: 
Wednesday, August 3, 2022 - 4:45pm

DUBLIN, Aug. 3, 2022 /PRNewswire/ -- The "Asia Pacific Healthcare Technology Management Market Size, Share & Industry Trends Analysis Report By Type of Services, By Facility Type, By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 3, 2022 /PRNewswire/ -- The "Asia Pacific Healthcare Technology Management Market Size, Share & Industry Trends Analysis Report By Type of Services, By Facility Type, By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • China's early reaction to coronavirus sickness in 2019 included the use of digital healthcare technology (COVID-19).
  • The China market dominated the Asia Pacific Healthcare Technology Management Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $4,098.6 million by 2028.
  • Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.